Primus In News
Indian pharma companies grows footprint in US cancer generics market
16-04-2025
Nilaya Varma, Group CEO & Co-Founder, Primus Partners, highlighted the strong healthcare demand in the US, driven by rising drug prices and a push for affordable care. He emphasized that the Affordable Care Act has boosted access, increasing demand for generics and biosimilars. Additionally, US efforts to diversify supply chains away from China are opening doors for Indian pharmaceutical firms, which are leveraging their generics experience and gaining global approvals through strategic partnerships.
Explore Related Insights
- The Business Standard Ep40: Financial inclusion and pvt banks, credit scores, and more
- Union budget 2024: FM Sitharaman announces three schemes to boost employment
- LIVE BLOG Budget 2024 Highlights Updates: Nirmala Sitharaman lists 9 developmental priorities in 83-minute Budget speech
- Refund for booked event ticket: Now Zomato allows you to sell your ticket, will other event booking platforms follow?